Journal of cutaneous medicine and surgery · 2026
Real-World Efficacy of Ritlecitinib in Adolescent Patients With Alopecia Areata: A 36 Week Monocentric Real-Life Observational Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Jundong, Zhang Zhuoer, Jian Jia, Li Min, Ji Ruxin, Tian Tian, Liang Xiaobing, Zhao Zhixiang, Tang Yan, Li Ji, Liu Fangfen, Shi Wei
Аннотация
BACKGROUND: Ritlecitinib represents the sole therapeutic agent currently approved for adolescents aged 12 to 17 years with severe alopecia areata (AA). Despite its regulatory endorsement, real-world data characterizing treatment outcomes and tolerability profiles in pediatric populations remain conspicuously absent.
OBJECTIVE: To systematically assess clinical response trajectories and treatment-emergent adverse events among adolescent AA patients treated with ritlecitinib in a real-world clinical cohort.
METHODS: We conducted a retrospective review of electronic medical records from December 2023 to May 2025, including AA patients aged 12 to 17 years treated with ritlecitinib. Data collected included demographics, AA severity scores [Severity of Alopecia Tool (SALT)], Eyebrow Assessment, Eyelash Assessment, and safety outcomes.
RESULTS: The study enrolled 30 patients aged 12 to 17 years, with a median baseline SALT score of 61.3 (interquartile range 40.5-88.25). Treatment was administered over a 36 week period. By week 36, clinically meaningful improvements in SALT scores were observed: 96.7% of patients achieved at least a 30% reduction, while 86.7% and 70.0% attained reductions of ≥50% and ≥80%, respectively. At this time point, 24 patients (80.0%) achieved SALT scores ≤20. Among patients with baseline eyebrow or eyelash involvement, sustained regrowth was observed throughout the treatment period. All 6 patients with eyebrow involvement and all 5 with eyelash involvement exhibited complete recovery. Adverse events were predominantly mild, with folliculitis representing the most frequently reported event (n = 7).
LIMITATIONS: Single-center, retrospective design.
CONCLUSIONS: Real-world utilization of ritlecitinib demonstrated robust efficacy in AA while maintaining a favorable safety profile among adolescent populations, with no novel safety signals identified beyond established pharmacovigilance parameters.
OBJECTIVE: To systematically assess clinical response trajectories and treatment-emergent adverse events among adolescent AA patients treated with ritlecitinib in a real-world clinical cohort.
METHODS: We conducted a retrospective review of electronic medical records from December 2023 to May 2025, including AA patients aged 12 to 17 years treated with ritlecitinib. Data collected included demographics, AA severity scores [Severity of Alopecia Tool (SALT)], Eyebrow Assessment, Eyelash Assessment, and safety outcomes.
RESULTS: The study enrolled 30 patients aged 12 to 17 years, with a median baseline SALT score of 61.3 (interquartile range 40.5-88.25). Treatment was administered over a 36 week period. By week 36, clinically meaningful improvements in SALT scores were observed: 96.7% of patients achieved at least a 30% reduction, while 86.7% and 70.0% attained reductions of ≥50% and ≥80%, respectively. At this time point, 24 patients (80.0%) achieved SALT scores ≤20. Among patients with baseline eyebrow or eyelash involvement, sustained regrowth was observed throughout the treatment period. All 6 patients with eyebrow involvement and all 5 with eyelash involvement exhibited complete recovery. Adverse events were predominantly mild, with folliculitis representing the most frequently reported event (n = 7).
LIMITATIONS: Single-center, retrospective design.
CONCLUSIONS: Real-world utilization of ritlecitinib demonstrated robust efficacy in AA while maintaining a favorable safety profile among adolescent populations, with no novel safety signals identified beyond established pharmacovigilance parameters.